Is the oral route possible for peptide and protein drug delivery?

Drug Discovery Today

Volumn 11, Issue 19-20, 2006, Pages 905-910

  Morishita, Mariko ^a   Peppas, Nicholas A ^b  

^a HOSHI UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTENNAPEDIA PROTEIN; BIOTIN; CHITOSAN; CYANOCOBALAMIN; FOLIC ACID; GLYCOPROTEIN P INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; HEMAGGLUTININ; INSULIN; INVASIN; LECTIN; MACROGOL; OLIGOARGININE; PENETRATIN; PEPTIDE; POLYGLACTIN; POLYMER; POLYPEPTIDE; PROTEIN; RIBOFLAVIN; TOXIN; TRANSACTIVATOR PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN;

BIOLOGICAL ACTIVITY; CELL MEMBRANE; CLINICAL TRIAL; DIABETES MELLITUS; DIFFUSION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; HUMAN; HYDROPHILICITY; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE ABSORPTION; MACROMOLECULE; MEMBRANE PERMEABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN DEGRADATION; REVIEW; TRANSPORT KINETICS;

ADMINISTRATION, ORAL; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; PEPTIDES; PROTEINS;

EID: 33748752402     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.08.005     Document Type: Review

References (75)

1. Frokjaer S., and Otzen D.D. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4 (2005) 298-306
2. Torchilin V.P., and Lukyanov A.N. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today 8 (2003) 259-266
3. Shah R.B., et al. Oral delivery of proteins: Progress and prognostication. Crit. Rev. Ther. Drug Carrier Syst. 19 (2002) 135-169
4. Mahato R.I., et al. Emerging trends in oral delivery of peptide and proteins. Crit. Rev. Ther. Drug Carrier Syst. 20 (2003) 153-214
5. Hamman J.H., et al. Oral delivery of peptide drugs. BioDrugs 19 (2005) 165-177
6. Camenisch G., et al. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 6 (1998) 317-324
7. Rubas W., et al. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J. Pharm. Sci. 85 (1996) 165-169
8. Bendayan M., et al. Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa. Diabetologia 37 (1994) 119-126
9. Agarwal V., and Khan M.A. Current status of the oral delivery of insulin. Pharm. Technol. 10 (2001) 76-90
10. Bastian S.E.P., et al. Transport of IGF-I across epithelial cell monolayers. J. Endocrinol. 162 (1999) 361-369
11. Morishita M., et al. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16 (1993) 68-72
12. Tozaki H., et al. Use of protease inhibitors to improve calcitonin absorption from the small and large intestine in rats. J. Pharm. Pharmacol. 50 (1998) 913-920
13. Ward P.D., et al. Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm. Sci. Technol. Today 3 (2000) 346-358
14. Salamat-Miller N., and Johnston T.P. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm. 294 (2005) 201-216
15. Salama N.N., et al. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58 (2006) 15-28
16. Fasano A. Novel approaches for oral delivery of macromolecules. J. Pharm. Sci. 87 (1998) 1351-1356
17. Prego C., et al. Transmucosal macromolecular drug delivery. J. Control. Release 101 (2005) 151-162
18. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev. 57 (2005) 1569-1582
19. Yen W.-C., and Lee V.H.L. Penetration enhancement effect of Pz-peptide, a paracellularly transported peptide, in rabbit intestinal segments and Caco-2 cell monolayers. J. Control. Release 36 (1995) 25-37
20. Morishita M., et al. Oral insulin delivery systems based on complexation polymer hydrogels. J. Drug Del. Sci. Tech. 16 (2006) 19-24
21. Morishita M., et al. Novel oral insulin delivery systems based on complexation polymer hydrogels: Single and multiple administration studies in type 1 and 2 diabetic rats. J. Control. Release 110 (2006) 587-594
22. Junginger H.E. Bioadhesive polymer systems for peptide delivery. Acta Pharm. Technol. 36 (1990) 110-126
23. Bernkop-Schnurch A., and Clausen A.E. Biomembrane permeability of peptides: Strategies to improve their mucosal uptake. Mini Rev. Med. Chem. 2 (2002) 295-305
24. Aoki Y., et al. Region-dependent role of the mucous/glycocalyx layers in insulin permeation across rat small intestinal membrane. Pharm. Res. 22 (2005) 1854-1862
25. Gangwar S., et al. Prodrug strategies to enhance the intestinal absorption of peptides. Drug Discov. Today 2 (1997) 148-155
26. Mizuma T., et al. Intestinal transport and metabolism of glucose-conjugated kyotorphin and cyclic kyotorphin: metabolic degradation is crucial to intestinal absorption of peptide drugs. Biochim. Biophys. Acta 1475 (2000) 90-98
27. Hichens M. A comparison of thyrotropin-releasing hormone with analogs: influence of disposition upon pharmacology. Drug Metab. Rev. 14 (1983) 77-98
28. Hashimoto M., et al. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm. Res. 6 (1989) 171-176
29. Goldberg M., and Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2 (2003) 289-295
30. Calceti P., et al. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci. 22 (2004) 315-323
31. Basu A., et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjugate Chem. 17 (2006) 618-630
32. Wang J., et al. Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Release 26 (2003) 369-380
33. Kipnes M., et al. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 26 (2003) 421-426
34. Kidron M., et al. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabetic Med. 21 (2004) 354-357
35. Han H.-K., and Amidon G.L. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2 (2000) E6
36. Varma M.V.S., et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48 (2003) 347-359
37. Russell-Jones G.J. Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium. J. Drug Target. 12 (2004) 113-123
38. Hwa Kim S. Folate receptor mediated intracellular protein delivery using PLL-PEG-FOL conjugate. J. Control. Release 103 (2005) 625-634
39. Lim C.J., and Shen W.C. Comparison of monomeric and oligomeric transferrin as potential carrier in oral delivery of protein drugs. J. Control. Release 106 (2005) 273-286
40. Bai Y., et al. Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7292-7296
41. Trehin R., and Merkle H.P. Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur. J. Pharm. Biopharm. 58 (2004) 209-223
42. Zorko M., and Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 57 (2005) 529-545
43. Schwarze S.R., et al. In vivo protein transduction: delivery of a biologically active protein. Science 285 (1999) 1569-1572
44. Liang J.F., and Yang V.C. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem. Biophys. Res. Commun. 335 (2005) 734-738
45. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?". J. Control. Release 109 (2005) 77-85
46. Goto T., et al. Novel mucosal insulin delivery systems based on fusogenic liposomes. Pharm. Res. 23 (2006) 384-391
47. Takeuchi H., et al. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J. Control. Release 86 (2003) 235-242
48. Brayden D.J., et al. Keynote review: Intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov. Today 10 (2005) 1145-1157
49. Shakweh M., et al. Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. J. Pharm. Biopharm. 61 (2005) 1-13
50. Desai M.P., et al. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14 (1997) 1568-1573
51. Pan Y., et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. 249 (2002) 139-147
52. Ma Z., et al. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int. J. Pharm. 293 (2005) 271-280
53. Garcia-fuentes M., et al. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25 (2005) 133-143
54. Florence A.T. Issues in oral nanoparticle drug carrier uptake and targeting. J. Drug Target. 12 (2004) 65-70
55. Aliabadi H.M., and Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin. Drug Deliv. 3 (2006) 139-162
56. Yuan X., et al. Stabilization of lysozyme-incorporated polyion complex micelles by the omega-end derivatization of poly(ethylene glycol)-poly(alpha,beta-aspartic acid) block copolymers with hydrophobic groups. Langmuir 21 (2005) 2668-2674
57. Mathot F., et al. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J. Control. Release 111 (2006) 47-55
58. Lewin M., et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18 (2000) 410-414
59. Tkachenko A.G., et al. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 15 (2004) 482-490
60. Kang H., et al. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res. 22 (2005) 2099-2106
61. Torchilin V.P., et al. Tat peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8786-8791
62. Tseng Y.L., et al. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol. Pharmacol. 62 (2002) 864-872
63. Marty C., et al. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell. Mol. Life Sci. 61 (2004) 1785-1794
64. Fawell S., et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 664-668
65. Datta K., et al. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res. 61 (2001) 1768-1775
66. Takenobu T., et al. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol. Cancer Ther. 1 (2002) 1043-1049
67. Hosotani R., et al. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin. Cancer Res. 8 (2002) 1271-1276
68. Mie M., et al. Intracellular delivery of antibodies using TAT fusion protein A. Biochem. Biophys. Res. Commun. 310 (2003) 730-734
69. Machova Z., et al. Cellular internalization of enhanced green fluorescent protein ligated to a human calcitonin-based carrier peptide. Chem. Biochem. 3 (2002) 672-677
70. Damge C., et al. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37 (1988) 246-251
71. Kawashima Y., et al. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol. 5 (2000) 77-85
72. Sang Yoo H., and Park T.G. Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. J. Pharm. Sci. 93 (2004) 488-495
73. Sakuma S., et al. Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int. J. Pharm. 239 (2002) 185-195
74. Chung H., et al. Self-assembled 'nanocubicle' as a carrier for peroral insulin delivery. Diabetologia 45 (2002) 448-451
75. Foss A.C., et al. Development of acrylic-based copolymers for oral insulin delivery. Eur. J. Pharm. Biopharm. 57 (2004) 163-169